TAK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Takeda Pharmaceutical Co Ltd (TAK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and bullish moving averages indicate long-term growth potential. Despite the lack of immediate trading signals, the overall outlook aligns with the investor's goals.
The stock's moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. However, the MACD histogram is negative and expanding, suggesting short-term weakness. RSI is neutral at 58.076, and the stock is trading near its pivot point of 18.523, with support at 18.284 and resistance at 18.762.
Takeda's Entyvio showed significant efficacy in a Phase 3 trial for ulcerative colitis in children, which could boost investor interest.
The company's stock is trading above its 20-day moving average, reflecting a positive trend.
Strong financial performance in Q3 2026, with revenue up 4.16% YoY and net income up 335.66% YoY.
MACD histogram is negative and expanding, indicating potential short-term weakness.
No significant hedge fund or insider trading trends in the last quarter.
In Q3 2026, Takeda's revenue increased by 4.16% YoY to 1,191,698,000,000. Net income surged by 335.66% YoY to 103,640,000,000, and EPS grew by 337.08% YoY to 65.65. Gross margin improved to 54.91%, up 5.94% YoY, showcasing strong financial health and growth.
H.C. Wainwright maintains a positive view on Takeda's partnered assets and creativity in transactions. The analyst highlights the company's depth and breadth in its pipeline and partnerships, which are expected to drive growth through 2026.
